The potential new copay accumulator rule could significantly impact prescription drug costs for patients, determining whether they face billions in additional expenses or savings.
Judge John D. Bates ruled that copay accumulators could only be used for brand-name pharmaceuticals with generic options, marking a significant shift in patient cost management.
Senators are urging HHS to abandon its appeal regarding copay accumulators to protect American consumers from unmanageable out-of-pocket drug expenses.
Carl Schmid emphasized the importance of copay assistance, stating that many patients face surprise bills for thousands of dollars once this support ends.
Collection
[
|
...
]